Ignite Creation Date:
2024-05-06 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 2:25 PM
Study NCT ID:
NCT05241093
Status:
RECRUITING
Last Update Posted:
2024-05-14
First Post:
2022-01-16
Brief Title:
A Study of HYML-122 and Cytarabine in Patients With FLT3 Positive Relapsed or Refractory Acute Myeloid Leukemia AML
Sponsor:
Tarapeutics Science Inc
Organization:
Tarapeutics Science Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-29
Start Date Type:
ACTUAL
Primary Completion Date:
2024-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-06-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-16
First Submit QC Date:
February 6 2022
Study First Post Date:
2022-02-15
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-13
Last Update Post Date:
2024-05-14
Last Update Post Date Type:
ACTUAL